Biodesix (BDSX) Revenue & Revenue Breakdown
Biodesix Revenue Highlights
Latest Revenue (Y)
$49.09M
Latest Revenue (Q)
$18.15M
Main Segment (Y)
Diagnostic Tests
Biodesix Revenue by Period
Biodesix Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $49.09M | 28.46% |
| 2022-12-31 | $38.21M | -29.89% |
| 2021-12-31 | $54.51M | 19.64% |
| 2020-12-31 | $45.56M | 85.55% |
| 2019-12-31 | $24.55M | 20.16% |
| 2018-12-31 | $20.43M | - |
Biodesix generated $49.09M in revenue during NA 2023, up 28.46% compared to the previous quarter, and up 240.25% compared to the same period a year ago.
Biodesix Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $18.15M | 1.26% |
| 2024-06-30 | $17.93M | 20.97% |
| 2024-03-31 | $14.82M | 1.02% |
| 2023-12-31 | $14.67M | 8.72% |
| 2023-09-30 | $13.49M | 13.64% |
| 2023-06-30 | $11.87M | 31.10% |
| 2023-03-31 | $9.06M | -5.75% |
| 2022-12-31 | $9.61M | -13.50% |
| 2022-09-30 | $11.11M | 1.43% |
| 2022-06-30 | $10.95M | 67.23% |
| 2022-03-31 | $6.55M | -9.36% |
| 2021-12-31 | $7.22M | 10.61% |
| 2021-09-30 | $6.53M | -45.05% |
| 2021-06-30 | $11.88M | -58.83% |
| 2021-03-31 | $28.87M | 6.80% |
| 2020-12-31 | $27.03M | 194.01% |
| 2020-09-30 | $9.19M | 116.87% |
| 2020-06-30 | $4.24M | -16.82% |
| 2020-03-31 | $5.10M | -38.39% |
| 2019-12-31 | $8.27M | 109.82% |
| 2019-09-30 | $3.94M | -36.11% |
| 2019-06-30 | $6.17M | - |
| 2019-03-31 | $6.17M | 20.78% |
| 2018-06-30 | $5.11M | - |
| 2018-03-31 | $5.11M | - |
Biodesix generated $18.15M in revenue during Q3 2024, up 1.26% compared to the previous quarter, and up 152.89% compared to the same period a year ago.
Biodesix Revenue Breakdown
Biodesix Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Diagnostic Tests | $45.19M | $34.54M | $48.94M | - |
| Service | - | $3.67M | $5.57M | - |
| Lung Diagnostic Revenue | - | - | - | $12.60M |
| C O V I D19 Diagnostic Test Revenue | - | - | - | $28.30M |
Latest
Biodesix's latest annual revenue breakdown by segment (product or service), as of Dec 23: Diagnostic Tests (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostic Tests | $17.17M | $13.80M | $12.80M | $12.30M | $11.45M | $8.64M | $8.26M | $10.44M | $10.21M | $5.63M | $5.87M | $5.04M | $10.84M | $27.20M | $25.12M | $8.55M |
| Service | - | - | - | $1.19M | $423.00K | $411.00K | $1.35M | $664.00K | $744.00K | $915.00K | $1.36M | $1.49M | $1.05M | $1.67M | $1.91M | $641.00K |
Latest
Biodesix's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Diagnostic Tests (100.00%).
Biodesix Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FONR | FONAR | $102.88B | $25.94M |
| GTH | Genetron | $650.71M | $201.32M |
| BNR | Burning Rock Biotech | $537.43M | $125.62M |
| LMDX | LumiraDx | $254.48M | $21.00M |
| CSTL | Castle Biosciences | $219.79M | $85.78M |
| OLK | Olink AB (publ) | $169.91M | $28.59M |
| STIM | Neuronetics | $71.35M | $16.45M |
| XGN | Exagen | $52.55M | $15.06M |
| BDSX | Biodesix | $49.09M | $18.15M |
| ENZ | Enzo Biochem | $31.91M | $8.02M |
| ACRS | Aclaris Therapeutics | $31.25M | $4.35M |
| PRE | Prenetics Global | $21.74M | $6.41M |
| DRIO | DarioHealth | $20.35M | $6.25M |
| SERA | Sera Prognostics | $306.00K | $24.00K |